PTC TherapeuticsFRA:BH3 -0.85%52 Gross Margin % is 89.72% as of Mar. 2026, which is 6% below its 10-year median of 95.03. GuruFocus rates FRA:BH3 with a GF Score™ of 52/100 and a GF Value™ of €30.85. The stock has 9 warning signs investors should review. Among 734 Biotechnology companies, PTC Therapeutics ranks better than 88.83% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PTC Therapeutics had a gross margin of 89.72% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PTC Therapeutics Gross Margin % Related Terms
PTC Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for PTC Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BH3 vs SRRK, COGT, RYTM: Gross Margin % Comparison
For the Biotechnology subindustry, PTC Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PTC Therapeutics (FRA:BH3) has a Gross Margin % of 89.72% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on PTC Therapeutics and its competitors. This is near median its historical median of 95.03. Over the past decade, PTC Therapeutics' Gross Margin % has ranged from 92.48 to 97.65. According to the industry distribution chart, PTC Therapeutics ranks #82 out of 734 companies in the Biotechnology industry, placing it in the top 11.2%.
Is PTC Therapeutics' Gross Margin % too high?
PTC Therapeutics' current Gross Margin % of 89.72% is near median its 10-year median of 95.03. Over the past 10 years, this metric has ranged from a low of 92.48 to a high of 97.65. The Biotechnology industry median Gross Margin % is 60.80. PTC Therapeutics' value of 89.72% is 47.6% above this industry median. Based on the distribution chart, PTC Therapeutics ranks #82 out of 734 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PTC Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Gross Margin % compare to SRRK and COGT?
According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #82 out of 734 companies for Gross Margin %. This places PTC Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.80. PTC Therapeutics' value of 89.72% is 47.6% above this benchmark. Historically, PTC Therapeutics' own Gross Margin % has ranged from 92.48 to 97.65 over the past decade. While the company's 10-year median is 95.03 vs. the industry median of 60.80, PTC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PTC Therapeutics's current Gross Margin % of 89.72% is 47.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PTC Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PTC Therapeutics's current Gross Margin % is 89.72%, which is near median its own 10-year median of 95.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Gross Margin % of 89.72%. The stock's GF Value™ is €30.85, compared to a current price of €70.32 — trading 127.9% above its estimated fair value. The current Gross Margin % is 89.72%, which is near median its 10-year median of 95.03 and 47.6% above the Biotechnology industry median of 60.80. PTC Therapeutics' overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Gross Margin % is 89.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of €70.32 is trading 127.9% above its estimated GF Value™ of €30.85.
Key valuation signals for FRA:BH3:
Gross Margin %: 89.72% (near median its 10-year median of 95.03)
GF Value™: €30.85 vs. price of €70.32 (127.9% above fair value)
Industry Position: 47.6% above the Biotechnology median (#82 of 734)
No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
52GF Score
Get the complete analysis for FRA:BH3
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BH3 has been successfully added to your 
